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ABSTRACT 
Objectives: The aim of the present study was to synthesize a series of novel bridged pyrans as antimicrobial agents. 
Methods: An isomeric mixture of 3-(4-ethoxy-10-methyl-8-oxo-2-phenyl-4,8-dihydro-2H-pyrano[3',2':6,7]chromeno[4,3-c]pyrazol-6-yl)-1-phenyl-
1H-pyrazole-4-carbaldehydes, 2(a-f) and 3-(4-ethoxy-8-methyl-10-oxo-2-phenyl-4,10-dihydro-2H-pyrano[2',3':5,6]chromeno[4,3-c]pyrazol-6-yl)-
1-phenyl-1H-pyrazole-4-carbaldehydes, 3(a-f) were synthesized by the reaction of 3,3'-(7-hydroxy-4-methyl-2-oxo-2H-chromene-6,8-diyl)bis(1-
phenyl-1H-pyrazole-4-carbaldehyde) 1(a-f) and ethyl alcohol in the presence of conc. H2SO4. The synthesized compounds were evaluated for their 
antimicrobial activity.  
Results: The structures of the new bridged pyran analogues 3-(4-ethoxy-10-methyl-8-oxo-2-phenyl-4,8-dihydro-2H-pyrano [3',2':6,7] chromeno 
[4,3-c]pyrazol-6-yl)-1-phenyl-1H-pyrazole-4-carbaldehydes, 2(a-f) and 3-(4-ethoxy-8-methyl-10-oxo-2-phenyl-4,10-dihydro-2H-pyrano [2',3':5,6] 
chromeno[4,3-c]pyrazol-6-yl)-1-phenyl-1H-pyrazole-4-carbaldehydes, 3(a-f) were confirmed by spectral studies and elemental analysis. The 
compounds 2e and 3e were having-CONH2 substitution and 2f and 3f were having-CSNH2 substitutions in the pyrazole rings showed antibacterial at 
minimum concentrations against all the tested organisms.  
Conclusions: Results of the antimicrobial activity reveal that some of the synthesized compounds act as potential antimicrobial agents against 
different fungal and bacterial organisms.  
Keywords: Antibacterial, Antifungal, Cyclisation, Formyl pyrazoles, Inhibitory. 
 
INTRODUCTION 
The construction of complex molecular architectures that exhibit greater 
biological potency in a facile and efficient manner remains an 
overarching goal for the chemists. In recent years coumarin libraries 
have attracted great attention because of their synthetic utility as 
building blocks for the construction of bioactive molecules. Coumarin 
derivatives are known to a wide range of activities; such as an 
antioxidant, antimicrobial, anti-HIV, antibiotic, anticancer, muscle 
relaxant, anti-inflammatory and anticoagulant properties [1]. An efficient 
synthesis of poly functionalized 4H-pyrans is carried out in one pot 
synthesis from an aldehyde, malononitrile and an active methylene 
diketo compound using a heterogeneous Mg/la mixed oxide catalyst [2]. 
A facile one-pot expeditious synthesis of 2-amino-4H-pyrans and 2-
amino-5-oxo-5, 6, 7, 8-tetrahydro-4H-chromenes under solvent-free 
conditions using magnesium oxide as a catalyst is reported [3].  
Pyrazole scaffolds drew a great deal of attention due to its 
contribution in biological and pharmacological fields [4]. The 
pyrazole nucleus has pronounced pharmacological applications such 
as anti-inflammatory [5], antimicrobial [6], antioxidant [7] and 
analgesic activity [8]. They have a long history of applications in 
agrochemicals and pharmaceutical industry as herbicides and active 
pharmaceuticals. 
In search of new antimicrobial agents and in continuation of our 
work on coumarin analogues we herein report the synthesis of a 
series of isomeric bridged pyrans tagged to pyrazole and coumarin 
skeleton and their antimicrobial activities. 
Experimental  
In a typical procedure, a series of isomeric bridged pyrans tagged to 
pyrazole and coumarin moiety 2(a-f) and 3(a-f) were synthesized by 
the condensation reaction of 3,3'-(7-hydroxy-4-methyl-2-oxo-2H-
chromene-6,8-diyl)bis(1-aryl-1H-pyrazole-4-carbaldehyde), 1(a-f) 
in ethyl alcohol (10 ml) in the presence of conc. H2SO4 (5 ml) under 
reflux conditions (Scheme-1). 
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Minimum inhibitory concentrations (MICs) were determined by 
broth dilution technique [9]. The nutrient broth, which contains 
logarithmic serially two-fold diluted amount of test compound and 
controls was inoculated with approximately 5 x 105 c. f. u of actively 
dividing bacteria cells. The bacterial cultures were incubated for 24 
h at 37 °C and fungi cultures were incubated for 72 h at 37 °C; the 
growth was monitored visually and spectrophotometrically. The 
lowest concentration required to arrest the growth of bacteria and 
fungi was regarded as minimum inhibitory concentration (MIC). The 
synthesized compounds were screened for their antibacterial 
activity against Escherichia coli, Bacillus substilis, Staphylococus 
aureus and antifungal activity against Aspergillus niger, Aspergillus 
flavus, C. albicans. The antibiotics streptomycin and nystatin were 
used as standard drugs against bacteria and fungi species 
respectively. The experiments were carried out in triplicate; the 
results were taken as a mean of three determinations. 
Melting points were determined by open capillary method and are 
uncorrected. IR spectra were recorded on a Nujol mull on Shimadzu 
8300 spectrometer. 1H NMR and 13C NMR spectra were recorded on 
Agilent-NMR 400 MHz and 125 MHz spectrophotometer 
respectively in CDCl3 with TMS as an internal standard. The chemical 
shifts are expressed in δ ppm. Mass spectra were obtained on Mass 
Lynx SCN781 spectrophotometer TOF mode. Elemental analysis was 
performed on a Thermo Finnigan Flash EA 1112 CHN analyzer. 
Chromatographic separations were carried out on silica gel (70-230 
mesh, Merck) column using hexane: ethyl acetate (9:2) as eluent. 
Typical procedure for synthesis of 3-(4-ethoxy-10-methyl-8-
oxo-2-phenyl-4,8-dihydro-2H-pyrano[3',2':6,7]chromeno[4,3-
c]pyrazol-6-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde, 2a  
To a solution of 3,3'-(7-hydroxy-4-methyl-2-oxo-2H-chromene-
6,8-diyl)bis(1-phenyl-1H-pyrazole-4-carbaldehyde), 1a (2.58g, 
0.005 mol) in ethyl alcohol (10 ml), concentrated sulfuric acid (5 
ml) was drop wise and the mixture was refluxed for 4 h at 80 °C. 
The progress of the reaction was monitored by TLC. After 
completion, the solvent was removed in vacuo. The resulting mass 
was extracted in to ether (30 ml), washed successively with NaOH 
and NaHCO3. The organic phase was dried over anhydrous sodium 
sulphate. The solvent was evaporated to dryness to get isomeric 
mixture of 3-(4-ethoxy-10-methyl-8-oxo-2-phenyl-4,8-dihydro-
2H-pyrano [3',2':6,7] chromeno [4,3-c]pyrazol-6-yl)-1-phenyl-1H-
pyrazole-4-carbaldehyde, 2a and 3-(4-ethoxy-8-methyl-10-oxo-2-
phenyl-4,10-dihydro-2H-pyrano [2',3': 5,6]chromeno[4,3-
c]pyrazol -6-yl)-1-phenyl-1H-pyrazole-4-carbal-dehyde, 3a 
(Scheme-1). The products were purified by column chromato-
graphy using hexane and ethyl acetate (9:2 v/v) as eluent. The 
same procedure was used in all cases.  




Solid in 59% (3.20g) yield; m. p. 192-194 °C. IR (Nujol, γ cm-1): 1772 
(s) (lactone C=O str), 1733 (s) (aldehyde C=O str), 1219 (s) (C-O str). 
1HNMR (CDCl3): δ 1.051 (t, 3H, CH3), 2.423 (s, 3H, CH3), 3.920 (q, 2H, 
OCH2), 6.026 (s, 1H, C9-H), 6.304 (s, 1H, C4-H), 7.423-7.728 (m, 12H, 
Ar-H), 8.320 (s, 1H, 5m ring-H), 9.782 (s, 1H, CHO). 13CNMR (CDCl3): 
δ 15.06 (1C, CH3), 20.13 (1C, CH3), 62.33 (1C, OCH2), 112.59 (1C), 
113.64 (1C), 114.87 (1C), 115.30 (1C), 116.02 (1C), 116.86 (1C), 
117.40 (1C), 119.72 (4C), 123.22 (1C), 126.16 (2C), 128.13 (1C), 
128.90 (4C), 130.17 (1C), 138.46 (2C), 147.80 (1C), 148.63 (1C), 
151.12 (1C), 152.94 (1C), 156.10 (1C), 161.18 (1C, C8), 181.32 (1C, 
CHO). MS (m/z): 545 (MH+), 544 (M+), 516, 488, 280 (100%, base 
peak), 236. Anal. Calcd. for C32H24N4O5: C, 70.58; H, 4.44; N, 10.29%; 





diyl)bis (1-(4-methyl phenyl)-1H-pyrazole-4-carbaldehyde), 1b 
(2.72g, 0.005 mol) as solid in 48% (2.75g) yield; m. p. 144-146 °C. IR 
(Nujol, γ cm-1): 1765 (s) (lactone C=O str), 1726 (s) (aldehyde C=O 
str), 1213 (s) (C-O str). 1HNMR (CDCl3): δ 1.089 (t, 3H, CH3), 2.314 (s, 
6H, CH3), 2.453 (s, 3H, CH3), 3.984 (q, 2H, OCH2), 6.066 (s, 1H, C9-H), 
6.202 (s, 1H, C4-H), 7.405-7.748 (m, 10H, Ar-H), 8.263 (s, 1H, 5m 
ring-H), 9.707 (s, 1H, CHO). 13CNMR (CDCl3): δ 15.62 (1C, CH3), 20.30 
(1C, CH3), 21.40 (2C, CH3), 62.66 (1C, OCH2), 112.16 (1C), 113.04 
(1C), 114.44 (1C), 115.33 (1C), 116.21 (1C), 119.42 (4C), 123.12 
(1C), 128.76 (1C), 129.32 (4C), 130.37 (1C), 134.78 (2C), 135.14 
(2C), 147.88 (1C), 148.66 (1C), 150.32 (1C), 151.64 (1C), 152.49 
(2C), 156.11 (1C), 161.36 (1C, C8), 180.66 (1C, CHO). MS (m/z): 573 
(MH+), 572 (M+), 544, 516, 280 (100%, base peak), 236. Anal. Calcd. 







(2.88g, 0.005 mol) as solid in 49% (2.95g) yield; m. p. 178-180 °C. IR 
(Nujol, γ cm-1): 1769 (s) (lactone C=O str), 1732 (s) (aldehyde C=O 
str), 1221 (s) (C-O str). 1HNMR (CDCl3): δ 1.126 (t, 3H, CH3), 2.394 (s, 
3H, CH3), 3.813 (s, 6H, OCH3), 3.955 (q, 2H, OCH2), 6.148 (s, 1H, C9-
H), 6.322 (s, 1H, C4-H), 7.361-7.707 (m, 10H, Ar-H), 8.123 (s, 1H, 5m 
ring-H), 9.869 (s, 1H, CHO). 13CNMR (CDCl3): δ 15.62 (1C, CH3), 20.30 
(1C, CH3), 55.40 (2C, OCH3), 62.10 (1C, OCH2), 111.32 (1C, C9), 
112.04 (4C), 113.20 (1C), 114.12 (4C), 114.93 (1C), 115.32 (1C), 
116.00 (1C), 117.56 (1C), 123.22 (1C), 130.30 (1C), 131.18 (1C), 
132.78 (2C), 145.06 (1C), 147.33 (2C), 151.44 (1C), 153.56 (1C), 
154.86 (1C), 157.08 (2C), 162.10 (1C, C8), 179.86 (1C, CHO). MS 
(m/z): 605 (MH+), 604 (M+), 576, 548, 280 (100%, base peak), 236. 
Anal. Calcd. for C34H28N4O7: C, 67.54; H, 4.67; N, 9.27%; Found: C, 





6,8-diyl) bis (1-(4-fluoro phenyl)-1H-pyrazole-4-carbaldehyde), 
1d (2.76g, 0.005 mol) as solid in 54% (3.15g) yield; m. p. 182-
185 °C. IR (Nujol, γ cm-1): 1763 (s) (lactone C=O str), 1724 (s) 
(aldehyde C=O str), 1213 (s) (C-O str). 1HNMR (CDCl3): δ 1.105 
(t, 3H, CH3), 2.343 (s, 3H, CH3), 3.908 (q, 2H, OCH2), 6.244 (s, 1H, 
C9-H), 6.440 (s, 1H, C4-H), 7.224-7.682 (m, 10H, Ar-H), 8.189 (s, 
1H, 5m ring-H), 9.804 (s, 1H, CHO). 13CNMR (CDCl3): δ 15.02 (1C, 
CH3), 20.14 (1C, CH3), 63.00 (1C, OCH2), 112.02 (1C, C9), 113.16 
(1C), 113.53 (1C), 114.32 (1C), 115.14 (4C), 115.52 (1C), 116.32 
(4C), 116.68 (1C), 117.26 (1C), 123.12 (1C), 128.18 (1C), 130.14 
(1C), 134.18 (2C), 146.23 (1C), 148.13 (1C), 150.65 (1C), 152.36 
(1C), 155.46 (1C), 159.28 (2C), 162.34 (1C, C8), 180.22 (1C, 
CHO). MS (m/z): 581 (MH+), 580 (M+), 552, 524, 280 (100%, base 
peak), 236. Anal. Calcd. for C32H22F2N4O5: C, 66.20; H, 3.82; N, 





6,8-diyl)bis(4-formyl-1H-pyrazole-1-carboxamide), 1e (4) 
(2.25g, 0.005 mol) as solid in 50% (2.39g) yield; m. p. 200-203 
°C. IR (Nujol, γ cm-1): 1771 (s) (lactone C=O str), 1730 (s) 
(aldehyde C=O str), 1217 (s) (C-O str). 1HNMR (CDCl3): δ 1.166 
(t, 3H, CH3), 2.404 (s, 3H, CH3), 3.902 (q, 2H, OCH2), 6.215 (s, 1H, 
C9-H), 6.363 (s, 1H, C4-H), 7.636 (s, 1H, C11-H), 7.923 (s, 4H, NH2), 
8.26 (s, 1H, 5m ring-H), 8.677 (s, 1H, 5m ring-H), 9.803 (s, 1H, 
CHO). 13CNMR (CDCl3): δ 15.56 (1C, CH3), 21.10 (1C, CH3), 62.24 
(1C, OCH2), 110.72 (1C), 112.46 (1C), 112.82 (1C, C9), 114.02 
(1C), 114.51 (1C), 115.66 (1C), 126.48 (1C), 128.88 (1C), 135.12 
(1C), 136.28 (1C), 142.33 (1C), 144.63 (1C), 147.54 (1C), 152.10 
(1C), 156.31 (1C), 157.30 (2C, CONH2), 161.14 (1C, C8), 167.22 
(1C, CHO). MS (m/z): 479 (MH+), 478 (M+), 450, 422, 280 (100%, 
base peak), 236. Anal. Calcd. for C22H18N6O7: C, 55.23; H, 3.79; N, 
17.57%; Found: C, 55.20; H, 3.64; N, 17.44%. 
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diyl)bis(4-formyl-1H-pyrazole-1-carbothioamide), 1f (4) (2.41g, 
0.005 mol) as solid in 56% (2.85g) yield; m. p. 174-178 °C. IR (Nujol, 
γ cm-1): 1766 (s) (lactone C=O str), 1735 (s) (aldehyde C=O str), 
1215 (s) (C-O str). 1HNMR (CDCl3): δ 1.101 (t, 3H, CH3), 2.414 (s, 3H, 
CH3), 3.882 (q, 2H, OCH2), 6.128 (s, 1H, C9-H), 6.343 (s, 1H, C4-H), 
7.638 (s, 1H, C11-H), 7.864 (s, 1H, 5m ring-H), 8.076 (s, 1H, 5m ring-
H), 8.622 (s, 4H, NH2), 9.844 (s, 1H, CHO). 13CNMR (CDCl3): δ 15.78 
(1C, CH3), 20.86 (1C, CH3), 62.68 (1C, OCH2), 111.72 (1C), 112.54 (1C, 
C9), 112.96 (1C), 114.88 (1C), 115.24 (1C), 116.12 (1C), 126.72 (1C), 
128.74 (1C), 135.27 (1C), 136.7 (1C), 142.21 (1C), 144.51 (1C), 
147.33 (1C), 152.32 (1C), 155.44 (1C), 162.36 (1C, C8), 174.10 (2C, 
CSNH2), 180.26 (1C, CHO). MS (m/z): 511 (MH+), 510 (M+), 482, 454, 
280 (100%, base peak), 236. Anal. Calcd. for C22H18N6O5S2: C, 51.76; 




Solid in 36% (1.95g) yield; m. p. 189-190 °C. IR (Nujol, γ cm-1): 1765 
(s) (lactone C=O str), 1728 (s) (aldehyde C=O str), 1214 (s) (C-O str). 
1HNMR (CDCl3): δ 1.052 (t, 3H, CH3), 2.422 (s, 3H, CH3), 3.940 (q, 2H, 
OCH2), 6.126 (s, 1H, C9-H), 6.316 (s, 1H, C4-H), 7.416-7.745 (m, 12H, 
Ar-H), 8.319 (s, 1H, 5m ring-H), 9.770 (s, 1H, CHO). 13CNMR (CDCl3): 
δ 15.22 (1C, CH3), 20.18 (1C, CH3), 62.21 (1C, OCH2), 112.50 (1C), 
113.50 (1C), 114.66 (1C), 115.43 (1C), 116.32 (1C), 116.88 (1C), 
117.68 (1C), 119.74 (4C), 123.98 (1C), 126.02 (2C), 128.10 (1C), 
128.94 (4C), 130.16 (1C), 138.41 (2C), 147.36 (1C), 148.60 (1C), 
151.06 (1C), 152.54 (1C), 152.10 (1C, C8), 156.15 (1C), 185.30 (1C, 
CHO). MS (m/z): 545 (MH+), 544 (M+), 516, 488, 442, 353, 249 
(100%, base peak). Anal. Calcd. for C32H24N4O5: C, 70.58; H, 4.44; N, 






(2.72g, 0.005 mol) as solid in 38% (2.17g) yield; m. p. 147-149 °C. IR 
(Nujol, γ cm-1): 1772 (s) (lactone C=O str), 1731 (s) (aldehyde C=O 
str), 1216 (s) (C-O str). 1HNMR (CDCl3): δ 1.123 (t, 3H, CH3), 2.281 (s, 
6H, CH3), 2.487 (s, 3H, CH3), 3.760 (q, 2H, OCH2), 6.112 (s, 1H, C9-H), 
6.306 (s, 1H, C4-H), 7.452-7.790 (m, 10H, Ar-H), 8.436 (s, 1H, 5m 
ring-H), 9.780 (s, 1H, CHO). MS (m/z): 573 (MH+), 572 (M+), 516, 
470, 249 (100%, base peak). Anal. Calcd. for C34H28N4O5: C, 71.32; H, 





diyl)bis (1-(4-methoxy phenyl)-1H-pyrazole-4-carbaldehyde), 1c (2.88g, 
0.005 mol) as solid in 37% (2.23g) yield; m. p. 172-174 °C. IR (Nujol, γ 
cm-1): 1770 (s) (lactone C=O str), 1730 (s) (aldehyde C=O str), 1222 (s) 
(C-O str). 1HNMR (CDCl3): δ 1.099 (t, 3H, CH3), 2.346 (s, 3H, CH3), 3.855 
(s, 6H, OCH3), 3.980 (q, 2H, OCH2), 6.133 (s, 1H, C9-H), 6.338 (s, 1H, C4-H), 
7.380-7.745 (m, 10H, Ar-H), 8.469 (s, 1H, 5m ring-H), 9.789 (s, 1H, CHO). 
13CNMR (CDCl3): δ 15.66 (1C, CH3), 20.38 (1C, CH3), 55.56 (2C, OCH3), 
62.19 (1C, OCH2), 112.08 (1C, C9), 112.22 (4C), 113.26 (1C), 114.56 (4C), 
114.98 (1C), 115.74 (1C), 116.08 (1C), 117.88 (1C), 123.20 (1C), 130.34 
(1C), 131.28 (1C), 132.26 (2C), 145.38 (1C), 147.40 (2C), 151.40 (1C), 
152.10 (1C, C8), 153.55 (1C), 154.92 (1C), 157.18 (2C), 183.32 (1C, CHO). 
Anal. Calcd. for C34H28N4O7: C, 67.54; H, 4.67; N, 9.27%; Found: C, 67.42; 





diyl)bis (1-(4-fluoro phenyl)-1H-pyrazole-4-carbaldehyde), 1d 
(2.76g, 0.005 mol) as solid in 36% (2.08g) yield; m. p. 177-178 °C. IR 
(Nujol, γ cm-1): 1775 (s) (lactone C=O str), 1734 (s) (aldehyde C=O 
str), 1224 (s) (C-O str). 1HNMR (CDCl3): δ 1.219 (t, 3H, CH3), 2.338 (s, 
3H, CH3), 3.914 (q, 2H, OCH2), 6.241 (s, 1H, C9-H), 6.466 (s, 1H, C4-H), 
7.220-7.686 (m, 10H, Ar-H), 8.185 (s, 1H, 5m ring-H), 9.820 (s, 1H, 
CHO). Anal. Calcd. for C32H22F2N4O5: C, 66.20; H, 3.82; N, 9.65%; 





diyl)bis(4-formyl-1H-pyrazole-1-carboxamide), 1e (2.25g, 0.005 
mol) and ethyl alcohol (0.002 mol) as solid in 36% (1.72g) yield; m. 
p. 205-206 °C. IR (Nujol, γ cm-1): 1762 (s) (lactone C=O str), 1722 (s) 
(aldehyde C=O str), 1112 (s) (C-O str). 1HNMR (CDCl3): δ 1.162 (t, 
3H, CH3), 2.404 (s, 3H, CH3), 3.923 (q, 2H, OCH2), 6.210 (s, 1H, C9-H), 
6.362 (s, 1H, C4-H), 7.646 (s, 1H, C7-H), 7.923 (s, 4H, NH2), 8.262 (s, 
1H, 5m ring-H), 8.672 (s, 1H, 5m ring-H), 9.834 (s, 1H, CHO). 13CNMR 
(CDCl3): δ 15.52 (1C, CH3), 21.48 (1C, CH3), 62.36 (1C, OCH2), 110.70 
(1C), 112.38 (1C), 112.80 (1C, C9), 114.00 (1C), 114.50 (1C), 115.42 
(1C), 126.43 (1C), 128.81 (1C), 135.10 (1C), 136.24 (1C), 142.30 
(1C), 144.23 (1C), 147.30 (1C), 152.56 (1C), 156.26 (1C), 151.30 (2C, 
CONH2), 152.14 (1C, C8), 187.20 (1C, CHO). MS (m/z): 479 (MH+), 
478 (M+), 450, 422, 249 (100%, base peak). Anal. Calcd. for 






diyl)bis(4-formyl-1H-pyrazole-1-carbothioamide), 1f (4) (2.41g, 
0.005 mol) as solid in 38% (1.93g) yield; m. p. 170-171 °C. IR (Nujol, 
γ cm-1): 1778 (s) (lactone C=O str), 1738 (s) (aldehyde C=O str), 
1226 (s) (C-O str). 1HNMR (CDCl3): δ 1.118 (t, 3H, CH3), 2.414 (s, 3H, 
CH3), 3.895 (q, 2H, OCH2), 6.129 (s, 1H, C9-H), 6.348 (s, 1H, C4-H), 
7.684 (s, 1H, C11-H), 7.846(s, 1H, 5m ring-H), 8.022 (s, 1H, 5m ring-
H), 8.560 (s, 4H, NH2), 9.789 (s, 1H, CHO). Anal. Calcd. for 
C22H18N6O5S2: C, 51.76; H, 3.55; N, 16.46%; Found: C, 51.88; H, 3.33; 
N, 16.26%. 
The structures of the synthesized compounds were provided by IR, 
1H NMR, 13C NMR, MS studies and elemental analysis. For instance, in 
IR spectra, the stretching frequencies of the compounds 2(a-f) and 
3(b-e) showed a strong absorption bands in the region 1778-1762 
cm-1and 1738-1722 cm-1 for lactone and aldehydic C=O bonds 
respectively. A strong and intense absorption band is absorbed in 
the region 1226-1112 cm-1was assigned to C-O bonds.  
In 1H NMR spectra, the compounds 2(a-f) and 3(a-f) showed the 
absorption signals due to aromatic and substituent protons in the 
expected region. The compounds 2(a-f) showed consistent pattern 
signals due to C9-H and C4-H appeared as singlet in the region δ 
6.000-6.100 ppm, and δ 6.200-6.300 ppm. The–CHO proton 
appeared as singlet in the region δ 9.700-9.900 ppm. While the 
compounds 3(a-f) showed consistent pattern signals due to C9-H and 
C4-H appeared as singlet in the region δ 6.120-6.150 ppm, and δ 
6.300-6.400 ppm. The–CHO proton appeared as singlet in the region 
δ 9.770-9.980 ppm. 
In 13C NMR, all compounds showed the signals due to aromatic 
and substituent carbons at the expected region. The carbonyl 
carbons absorbed in the region δ 179.00-185.00 ppm. The 
synthesized compounds 2(a-f) showed significantly stable 
molecular ion peaks with a relative abundance ranging up to 18-
66% and the base peak at m/z 280; While 3(a-f) showed a base 
peak at m/z 249. Further, all compounds showed satisfactorily 
CHN analysis with a deviation of±0.20% from the theoretically 
calculated values, which strongly favor the formation of the 
products. 
The results of MICs) of the synthesized compounds 2(a-f) and 3(a-f) 
tested against different bacterium were tabulated in table-1.
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Table 1: MIC’s of the synthesized compounds 2(a-f) and 3(a-f) tested against bacteria species 
Compound Minimum inhibitory concentrations in µg/ml 
S. aureus B. substilis E. coli 
2a 50 ** 200 
2b 100 ** 100 
2c 50 ** 150 
2d 50 ** 200 
2e 25 150 50 
2f 25 100 50 
3a 150 200 150 
3b 200 200 150 
3c 150 150 200 
3d 150 200 150 
3e 25 50 25 
3f 25 25 50 
Streptomycin 25 50 25 
Values are expressed as mean of the three determinations (n=3), **No inhibition observed even at a higher concentration of 200 µg/ml 
 
The synthesized compounds exerted moderate to good antibacterial 
activity against the tested organisms. Compounds 2(a-d) failed to 
show antibacterial activity against B. substilis even at a 
concentration higher than 200 µg/ml, but showed moderate activity 
against the species S. aureus and E. coli. Compounds 3(a-d) showed 
moderate activities against all the bacterium tested. Compounds 2e 
and 3e were having-CONH2 substitution and 2f and 3f were having-
CSNH2 substitutions in the pyrazole rings showed antibacterial at 
minimum concentrations against all the tested organisms.  
The results of MICs) of the synthesized compounds 2(a-f) and 3(a-f) 
tested against different fungi species were tabulated in table-2.
 
Table 2: MIC’s of the synthesized compounds 2(a-f) and 3(a-f) tested against fungi species 
Compound Minimum inhibitory concentrations in µg/ml 
A. niger A. flavus C. albicans 
2a 100 200 100 
2b 100 150 150 
2c 200 150 150 
2d 150 200 100 
2e 50 50 25 
2f 25 50 25 
3a 100 150 150 
3b 150 150 100 
3c 200 150 200 
3d 100 20 150 
3e 25 50 25 
3f 25 50 50 
Nystatin 25 50 25 
Values are expressed as mean of the three determinations (n=3). 
 
The synthesized compounds showed promising antifungal activity 
against the tested organisms. Compounds 2(a-d) and 3(a-d) showed 
moderate activities against all the bacterium tested in comparison 
with that of the reference standard. Compounds 2e and 3e were 
having-CONH2 substitution and 2f and 3f were having-CSNH2 
substitutions in the pyrazole rings showed antifungal activities at 
minimum concentrations against all the tested organisms. 
CONCLUSION 
The synthesized compounds showed promising in vitro antifungal 
activity against the tested organisms. The compounds 2e and 3e 
were having-CONH2 substitution and 2f and 3f were having-CSNH2 
substitutions in the pyrazole rings showed antibacterial and 
antifungal activity at minimum concentrations against all the tested 
organisms. Their MIC values indicate that these compounds act as 
potential antimicrobial agents. The compounds 2(a-d) and 3(a-d) 
showed antimicrobial activity at a higher concentration comparison 
with those of standard antibiotics used as reference drugs. 
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